|
Published by: Visiongain
Published: Feb. 23, 2009 - 137 Pages
Table of Contents
- 1 Executive Summary
- 1.1 Inflammatory Bowel Diseases (IBD) Market Trajectory
- 1.1.1 Visiongain’s Prediction for the IBD Market
- 1.1.2 Prevalence Rates Rising Worldwide
- 1.2 Aims, Scope and Format of the Report
- 1.2.1 Chapter Outline
- 1.3 Complexities of the IBD Market: Assessing Multiple Drug Categories
- 1.4 Research Methods
- 2 What Is Inflammatory Bowel Disease?
- 2.1 Definition and Diagnosis
- 2.2 Signs, Symptoms and Secondary Conditions
- 2.2.1 Bleeding Ulcers, Fistulae, Bowel Perforations, Toxic Megacolon
- 2.2.2 Pyoderma Gangrenosum
- 2.2.3 Primary Sclerosing Cholangitis
- 2.2.4 Malnutrition, Poor Nutrient Absorption and Stunting
- 2.3 Ulcerative Colitis
- 2.4 Crohn's Disease
- 2.5 Indeterminate Colitis: Distinguishing Crohn's Disease from Ulcerative Colitis
- 2.6 Causes / Aetiology of Inflammatory Bowel Disease
- 2.7 Prevalence
- 2.8 Socioeconomic Costs
- 2.8.1 The Individual Cost of IBD
- 3 Autoimmune Disorders
- 3.1 Brief Overview of the Immune System
- 3.2 What are Autoimmune Diseases / Disorders?
- 3.3 What Causes Autoimmune Disorders?
- 3.4 Why are Autoimmune Diseases Spreading in Developed Countries, but Not in Developing Countries?
- 3.4.1 The Hygiene Hypothesis
- 3.5 What Inflammation is and Why Inflammation is Dangerous
- 3.5.1 What is Inflamed in Inflammatory Bowel Disease?
- 3.5.2 The Costs and Consequences of Non-Treatment
- 4 Treatments for Inflammatory Bowel Diseases
- 4.1 The Goals of IBD Treatment
- 4.1.1 Producing Remission
- 4.1.2 Maintaining Remission
- 4.2 Drug Categories and their Mechanisms of Action
- 4.2.1 Aminosalicylates / 5-ASA / Mesalazine / Mesalamine
- 4.2.2 Corticosteroids
- 4.2.3 Immunomodulators
- 4.2.4 Antibiotics
- 4.2.5 Biologic Therapies / Monoclonal Antibodies
- 4.3 Surgical Treatments
- 4.3.1 Surgery for Ulcerative Colitis
- 4.3.2 Surgery for Crohn's Disease
- 4.4 The Leading Alternative Treatments: Hygiene Theory, Helminthic Therapy and Faecal Bacteriotherapy
- 4.4.1 Helminthic Therapy
- 4.4.2 Faecal / Fecal Bacteriotherapy / Human Probiotic Infusions (HPI)
- 4.4.3 Smoking
- 5 World IBD Market: Market Projection, Top Drug Projections
- 5.1 World Inflammatory Bowel Diseases Market, 2009-2024
- 5.1.1 The 5 Types of IBD Drugs
- 5.1.2 Other Drugs Cross-Indicated for IBD: Accounting for Monoclonal Antibodies
- 5.2 Lialda: Easier to Use, Growing in Significance
- 5.2.1 Unique Selling Point: Lialda is Lactose-Free
- 5.2.2 Lialda's Downside
- 5.3 Asacol
- 5.4 Entocort
- 5.4.1 Steroid Side Effects and Entocort EC
- 5.5 Pentasa
- 5.5.1 Excellent Safety Profile Assisting Pentasa's Sales
- 5.6 Salofalk
- 5.6.1 Salofalk Once-Daily
- 5.6.2 Salofalk and China Medical Sales Agreement
- 5.7 Budenofalk: 22% growth last year
- 5.7.1 Sales to be Boosted by New Sales Deal with Salix
- 5.8 Colazal: Losing Ground
- 5.9 Monoclonal Antibodies Forecasts
- 5.10 Remicade
- 5.10.1 Label Expansion Assisting Remicade's Sales
- 5.11 Humira
- 5.11.1 Label Expansion Behind Humira's Growth
- 5.11.2 Registered for Crohn's in US and EU; In Phase III for Crohn's in Japan
- 5.12 Cimzia
- 5.12.1 Challenged by the Committee for Medicinal Products for Human Use
- 5.13 Tysabri
- 5.13.1 Still Under Scrutiny for Liver Toxicity
- 6 Crucial Pipeline Developments: New Drug Targets, Innovative Delivery Technologies, and Cutting-Edge Treatments
- 6.1 Traficet-EN
- 6.2 Alicaforsen: Approved for Pouchitis, Cancelled for Crohn's, Under Assessment for UC
- 6.3 Rifaxamin
- 6.4 Myoconda: Is this the Cure for IBD?
- 6.5 Bupropion (Wellbutrin)
- 6.6 Abatacept (Orencia)
- 6.7 Polyketals: Technology to Deliver Drugs to Internal Inflammation
- 6.8 Extracorporeal Photopheresis (Light Therapy Outside of the Body): Uvadex (Methoxsalen)
- 6.9 A New Monoclonal Antibody Indicated for Crohn's Disease: Ustekinumab (Stelara)
- 6.10 Interleukins: Promising New Drug Targets (with a Table of Pipeline Interleukin Drugs)
- 6.11 Stem Cells: Prochymal by Osiris Therapeutics
- 7 Leading Companies
- 7.1 Procter & Gamble: 27% of the IBD Market
- 7.2 Ferring: Drug Originator and Innovator, but Limited Late-stage Pipeline
- 7.3 Shire
- 7.3.1 Lialda's Success and its Potential
- 7.3.2 Shire's Share of Pentasa
- 7.4 Dr. Falk
- 7.5 Prometheus Laboratories: Significance through IBD Drugs and Tests
- 7.5.1 Prometheus's Diagnostic and Genetic Analysis Tests: Frontiers of IBD Treatment
- 7.5.2 Serology Retrospective Results
- 7.5.3 Prometheus and Monoclonal Antibodies
- 7.6 Salix: Losing Colazal, Gaining US License to Budenofalk
- 7.7 Cosmo Pharmaceuticals / Cosmo Technologies: Watch this Company!
- 7.7.1 MMX Revenues
- 8 World Markets by Region
- 8.1 Changing Regional Market Share
- 8.2 North America: Slower Growth, Market Share in 2024 Compared with 2009
- 8.3 Europe: Retaining Market Share in the Long Term?
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 Poland: Increasing in Market Relevance
- 8.4 Africa, Asia, Australasia: Growing Markets
- 8.4.1 The Incidence and Prevalence of IBD in Asia
- 8.4.2 Japan
- 8.4.3 Australia
- 8.4.4 China
- 8.4.5 India
- 8.5 Latin America
- 9 Strengths, Weaknesses, Opportunities and Threats of the IBD Market
- 9.1 Strengths
- 9.1.1 Monoclonal Antibodies: a Threat to Intestinal Anti-Inflammatories?
- 9.2 Weaknesses
- 9.2.1 Genotyping: A Dead End?
- 9.3 Opportunities
- 9.4 Threats
- 9.4.1 Cures and/or Vaccines?
- 9.4.2 Market Saturation
- 9.4.3 The World Economic Climate - Will this Limit Uptake of New IBD Drugs in a Nearly-Saturated Market?
- 10 Visiongain Interviews with Relevant Key Opinion Leaders
- 10.1 Interview with Marco Greco, Chairman of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA).
- 10.1.1 Public Awareness
- 10.1.2 Differences Between European Countries
- 10.1.3 Drug Companies’ Involvement in Awareness Campaigns
- 10.1.4 Unmet Medical Needs
- 10.2 Interview with Dr. Alan Fraser, Associate Professor of Medicine, University of Auckland, Director for Clinical Examinations at Auckland Hospital.
- 10.2.1 Autoimmunity vs. Infection Theories
- 10.2.2 Monoclonal Antibodies
- 10.2.3 Genotyping
- 10.2.4 Remaining Therapeutic Gaps
- 10.2.5 Future Treatments
- 10.3 Interview with Professor Thomas Borody, MD, PhD, Director of the Centre for Digestive Diseases (Sydney), and Executive Director and Chief Medical Officer of Giaconda Limited
- 10.3.1 Mycobacterium avium paratuberculosis (MAP) Infection and IBD Aetiology
- 10.3.2 IBD and HIV/AIDS
- 10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments
- 10.3.4 Potential Cure(s)
- 10.3.5 Remicade and MAP
- 10.3.6 Genotyping
- 10.3.7 Crohn’s vs. Colitis
- 10.3.8 Future Therapies
- 10.3.9 Potential and Future of Myconda
- 11 Conclusions
- 11.1 IBD Market Sales Forcasts
- 11.2 The Market will be Stimulated by New Delivery Technologies and New Drug Targets
- 11.3 Many Drugs and Generics on the Market, but Poor Disease Management Means High Potential Drug Uptake
- 11.4 The IBD Market - Will Sales Growth Continue Steadily from 2009 to 2024?
- List of Tables
- Table 3.1 The Most Common Autoimmune Disorders, by Type
- Table 4.1 IBD Drugs by Type, Chemical Name and Brand Name
- Table 5.1 World Intestinal Anti-Inflammatories Sales Forecasts, 2009-2024
- Table 5.2 Lialda Sales Forecast, 2009-2024
- Table 5.3 Asacol Sales Forecast, 2009-2024
- Table 5.4 Entocort Sales Forecast, 2009-2024
- Table 5.5 Pentasa Sales Forecast, 2009-2024
- Table 5.6 Salofalk Sales Forecast, 2009-2024
- Table 5.7 Budenofalk Sales Forecast, 2009-2024
- Table 5.8 Colazal Sales Forecast, 2009-2024
- Table 5.9 Autoimmune-Indicated Monoclonal Antibodies Forecasts, 2009-2024
- Table 5.10 Remicade Sales Forecast, 2009-2024
- Table 5.11 Humira Sales Forecast, 2009-2024
- Table 5.12 Cimzia Sales Forecast, 2009-2024
- Table 5.13 Tysabri Sales Forecast, 2009-2024
- Table 6.1 Interleukin-targeted Drugs Pipeline, by Phase and Company, 2008
- Table 8.1 World Intestinal Anti-Inflammatories Sales Forecasts, 2009-2024
- Table 8.2 World Market Sales Forecasts by Region, 2009-2024
- Table 8.3 North America Sales Forecast, 2009-2024
- Table 8.4 Europe Sales Forecast, 2009-2024
- Table 8.5 Africa, Asia, Australasia Sales Forecast, 2009-2024
- Table 8.6 Latin America Sales Forecast, 2009-2024
- Table 9.1 Strengths and Weaknesses in the IBD Market
- Table 9.2 Opportunities and Threats in the IBD Market
- List of Figures
- Figure 2.1 Direct and Indirect Medical Costs of IBD in 4 Countries
- Figure 5.1 World Intestinal Anti-Inflammatories Market Projection, 2009-2024
- Figure 5.2 IBD Market Breakdown by Drug Type, 2008
- Figure 5.3 Top-Selling IBD Drugs, 2008
- Figure 5.4 Sales Forecasts of Top-Selling IBD Drugs, 2009-2024
- Figure 5.5 Lialda Sales Forecast, 2009-2024
- Figure 5.6 Asacol Sales Forecast, 2009-2024
- Figure 5.7 Entocort Sales Forecast, 2009-2024
- Figure 5.8 Pentasa Sales Forecast, 2009-2024
- Figure 5.9 Salofalk Sales Forecast, 2009-2023
- Figure 5.10 Budenofalk Sales Forecast, 2009-2024
- Figure 5.11 Colazal Sales Forecast, 2009-2024
- Figure 5.12 Autoimmune-indicated Monoclonal Antibodies Forecast
- Figure 5.13 Remicade Sales Forecast, 2009-2024
- Figure 5.14 Humira Sales Forecast, 2009-2024
- Figure 5.15 Cimzia Sales Forecast, 2009-2024
- Figure 5.16 Tysabri Sales Forecast, 2009-2024
- Figure 7.1 Top IBD Companies, 2008
- Figure 8.1 World Intestinal Anti-Inflammatories Sales Forecast, 2009-2024
- Figure 8.2 Regional Sales Forecasts, 2009-2024
- Figure 8.3 Market Share by World Region, 2014 Projection
- Figure 8.4 Market Share by World Region, 2024 Projection
- Figure 8.5 North America Sales Forecast, 2009-2024
- Figure 8.6 Europe Sales Forecast, 2009-2024
- Figure 8.7 Africa, Asia, Australasia Sales Forecast, 2009-2024
- Figure 8.8 Latin America Sales Forecast, 2009-2024
-
AbstractThis brand new in-depth market analysis examines the current and future prospects of the inflammatory bowel diseases (IBD) market. The world market for intestinal anti-inflammatories was worth over $2400 million in 2008, and had grown at 9% over the previous year.
The value of other types of drugs used to treat IBD, including immunosuppressants and monoclonal antibodies, approached $12000m. Visiongain predicts the market for intestinal anti-inflammatories and IBD drugs to continue expanding, based on rising disease rates and evolving diagnostic methods. Currently, IBD is under-diagnosed, especially in developing countries. As governments and health services address chronic illnesses like IBD, this market will expand into previously untreated regions. Continuing studies and surveys indicate that IBD is spreading globally, and has an especially high prevalence rate in India. In addition, the Latin American countries experienced 14% sales growth last year, and are set to account for an increasingly large share of the world market in years to come.
This report - Inflammatory Bowel Diseases: World Market 2009-2024 - discusses and analyses the major drug categories used in the treatment of IBD. This report forecasts the top brand-name and generic drugs used for IBD, including monoclonal antibody therapies. How much of an impact will monoclonal antibodies have on sales of other IBD-related therapies, for example? You should know and ths report will tell you. This report also analyses the major markets worldwide, discussing the principal national markets in detail, in addition to the world market. Through this report, you will discover how the leading markets will perform in the future, and how the relative values of each region will change over time. The US was the largest market in 2008, but will it retain its leading market share until 2024? How will the European market share compare with the Asian market share in 2014, 2019 and 2024?
Drug types analysed and forecasted in this report - Inflammatory Bowel Diseases: World Market 2009-2024 - include:
- Aminosalicylate acid / 5-ASA
- Corticosteroids
- Immunomodulators
- Antibiotics
- Biologic therapies
- Monoclonal antibodies.
- Includes unique primary material unavailable elsewhere
This report covers disease and therapy distinctions between the two major types of IBD: Crohn’s disease and ulcerative colitis. It discusses these diseases and addresses aetiological theories that impact upon treatment. We provide the information you need to assess the future of those diseases and of the relevant markets. Sources consulted include industrial databases, commercial information, published economic research and market-specific interviews with experts in the IBD field. The result is a comprehensive market- and industry-based report with detailed analyses and informed opinion that you will not find anywhere else.
In particular, Inflammatory Bowel Diseases: The World Market 2009-2024 focuses on the following essential aspects of that market:
- Forecast of the overall world IBD market from 2009 to 2024
- Forecasts of the current leading drugs’ sales from 2009 to 2024
- Assessments of pipeline developments
- Analyses of short- and long-term drivers in the market
- Analyses of how disease theories impact upon treatment procedures
- Sales forecasts for the leading regional markets from 2009 to 2024, including discussions of specific country markets
- Discussion of the importance of generics in the IBD market
- Discussion of why the market contains so many types of drugs, and what that means for future developments
- Assessments of opportunities and threats in the IBD market worldwide
- Analyses of the impact monoclonal antibodies will have on the IBD market, present and future.
Why you should buy this report:
- To receive a comprehensive assessment of the complex IBD market, including the various types of therapies
- To receive a comprehensive analysis of the sales prospects for existing and new IBD drugs from 2009 to 2024
- To discover which types of therapies are most likely to succeed over the short- and long-term, and why each will succeed
- For a thorough assessment of the current and future market at global and regional levels
- To find out where the market is heading, both technologically and commercially
- For a logical analysis of the multifaceted treatment options for IBD, including market drivers and restraints.
The global IBD market is highly complex, with multiple drugs being used simultaneously and/or sequentially for therapy. The market can therefore accept a large number of drugs, but the market is already fairly saturated, with several similar drugs on the market. What does such saturation mean for the futures of existing drugs? What does this mean for the pipeline? If, as visiongain’s interviewees say, IBD current drugs are less efficacious than they could be, what then are the promising future treatments that could fill therapeutic gaps? This report covers those important matters, amongst others.
As inflammatory bowel disease rates continue to rise, as too public awareness spreads and more-thorough diagnostic procedures expand the number of patients, the demand for IBD drugs will increase. What drugs and which companies will meet these therapeutic needs successfully in the future? Can new and future therapies compete successfully with established treatments? This report answers those and other important questions, to enable you to take advantage of this expanding market.
Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
